KR20200001199A - Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Skin Wrinkle as Active Ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing or alleviating skin wrinkles comprising ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol as an active ingredient. The composition of the present invention inhibits the expression of MMP-1 protein in human dermal fibroblasts, increases the production of type I procollagen, and inhibits the expression of IL-6 protein, thereby representing a synergetic effect of preventing generation of skin wrinkles and alleviating wrinkles on damaged skin. Overall, the composition of the present invention can prevent and greatly alleviate skin wrinkles.

Description

Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol as active ingredients Skin Wrinkle as Active Ingredient}

The present invention relates to a composition for preventing or improving skin wrinkles, and more particularly to a composition for preventing or improving skin wrinkles containing ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol as an active ingredient. It is about.

Skin wrinkles are known to be affected by various factors such as skin moisture content, collagen content, and immunity to the external environment. The most important factors affecting the formation of double wrinkles are collagen production and collagenase, a collagen degrading enzyme. Naze expression and activity.

Collagen is present in the dermis of the skin and is known as a major ingredient that gives skin elasticity with elastin, which accounts for about 70% to 80% of the total dry weight of the skin. Collagen decreases due to internal factors such as decreased cellular activity due to natural aging, and decreases biosynthesis or promotes degradation by external factors such as increased stress in various harmful environments or increased free radical species caused by sunlight. .

On the other hand, overproduction of reactive oxygen species (ROS) has been reported in UVB exposure environments, and signaling systems associated with UVB exposure include MAPKs (mitogen activated protein kinases), extracellular signal-regulated kinase (ERK), It is associated with proteins such as p38 kinase, and c-Jun amino-terminal kinase (JNK), which induces increased expression of NF-ĸB and AP-1 transcription factors. In addition, AP-1 protein is associated with the activity of matrix metallo-proteinase (MMP) gene, and NF-ĸB protein affects the expression of proinflammatory cytokines such as interleukin.

The breakdown of collagen and elastin in aged skin is mainly caused by increased expression of its degrading enzymes, such as MMP proteins. In addition, proinflammatory cytokines interfere with the synthesis of collagen and promote the breakdown of collagen. Type I collagen is the most abundant protein in the extracellular matrix of connective tissue. Extracellular matrix includes other types of proteins such as type III, V, and VII collagen, elastin, proteoglycans, fibronectin.

Controlling the expression level of type I collagen protein is the most important factor in preventing skin photoaging. Irradiation of UVB reduces expression of collagen precursor procollagen in skin fibroblasts through inhibition of the TGF-β / Smad signaling system. In addition, the TGF-β1 signaling system is one of the important factors regulating the synthesis of extracellular matrix in human skin fibroblasts.

Thus, the generation of reactive oxygen species (ROS) regulated by AP-1 and MAPKs factors, and the expression of MMPs, ILs, TGF-β, and type I procollagen, serve as useful markers in skin photoaging studies.

As such, various attempts have been made to search for natural substances that are effective in improving skin wrinkles by inhibiting collagen reduction. In order to take advantage of collagen's anti-wrinkle effect, products containing collagen were added to external skin composition such as cosmetics or ointment.However, these products are applied to the surface of the skin by applying collagen itself. Could not be effective. In order to solve these problems, interest in collagen synthesis promoters has increased, and conventionally known collagen synthesis promoters include vitamin C, retinoic acid, transforming growth factor (TGF), and protein derived from animal placenta (JP08). -231370), betulinic acid (betulinic acid, JP08-208424), chlorella extract (JP09-40523, JP10-36283, fibroblast proliferation). However, there is a problem in that the use of the material is limited to the amount of use due to safety problems such as irritation and redness when applying the skin, or the effect is insignificant, and thus, the wrinkle improvement effect cannot be expected. Therefore, there is an urgent need for the development of new wrinkle improvement compositions that are safer in vivo and have higher wrinkle improvement effects than conventional compositions for wrinkle improvement.

On the other hand, red ginseng is a material used in medicinal herbs for a long time, regarding the skin wrinkle improvement effect of red ginseng, Korean Patent Publication No. 10-2011-0060001, Korean Patent Publication No. 10-2011-0048699, Korea Korean Unexamined Patent Publication No. 10-2011-063912, Korean Unexamined Patent Publication No. 10-2011-0063916 and the like disclose the skin condition improvement function of red ginseng and red ginseng-derived saponins. In addition, Korean Patent Registration Publication No. 10-1469810, Korean Patent Registration Publication No. 10-1460569, etc. disclose effects such as wrinkle improvement, skin whitening and acne improvement of ginsenoside F2 which is one of the active ingredients of red ginseng. have.

In addition, Japanese Patent Application Laid-open No. 10-2016-0167064, which has been studied and filed by the present inventors, separates gastrodigenin from cheonma and binds glucose in α-glycoside form to form α-gastrodine (4-alpha-D- The anti-wrinkle effect of the new material produced by processing and modifying to glucopyranosiloxy benzyl alcohol) form is known.

Under the above background, the present inventors have diligently researched to maximize their synergistic effects on various ingredients known to have an excellent effect on improving skin wrinkles. As a result, ginsenoside F2 and 4-alpha-D -Combination of glucopyranosiloxy benzyl alcohol to the photoaging of human dermal fibroblasts (NHDFs) induced by UVB irradiation confirmed that it has an excellent effect on the prevention and improvement of skin wrinkles, complete the present invention Was done.

Accordingly, a main object of the present invention is to provide a composition having an excellent effect on the prevention or improvement of skin wrinkles by using ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol as an active ingredient.

According to an aspect of the present invention, the present invention provides a skin wrinkle prevention comprising ginsenoside F2 and 4-alpha-D-glucopyranosoxyoxy benzyl alcohol as an active ingredient or It provides a cosmetic composition for improvement.

The inventors of the present invention sought to find a material that is effective in improving skin wrinkles and preventing skin aging, and identified materials effective for improving skin wrinkles among various natural substances, and intensive research efforts were made to find a mixing ratio that can maximize the synergistic effects thereof. As a result, 4-alpha-D-glucopyrano produced by ginsenoside F2 derived from red ginseng and gasobidigenin (Gastrodigenin, 4-Hydroxybenzyl alcohol) from cellobiose as a sugar donor It was found that the combination of siloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol, α-gastrodine) showed a synergistic effect on the prevention and improvement of skin wrinkles, and also confirmed that there is no safety problem when applied to the skin. .

'Ginsenoside F2' of the present invention is a kind of ginseng saponin (Saponin) contained in ginseng, red ginseng, white ginseng, ginseng, rice ginseng, and wild ginseng cultured roots. ) -20- (β-D-glucopyranosyloxy) dammar-24-ene-12β-ol ', the molecular formula is C ₄₂ H ₇₂ O ₁₃ , molecular weight is 785.01 is a substance of the formula [1] Has a structure.

[Formula 1]

In addition, the compound '4-alpha-D-glucopyranosyloxy benzyl alcohol' of the present invention has a molecular formula of C ₁₃ H ₁₈ O ₇ , and has a molecular weight of 286.28. , Has the molecular structure of the following [Formula 2].

[Formula 2]

The 4-alpha-D-glucopyranosyloxy benzyl alcohol is made of Gastrodigenin (4-Hydroxybenzyl alcohol), which is a natural ingredient contained in Cheonma, as a sugar receptor. By using cellobiose as a sugar donor, enzymes such as cellulase and α-glucosidase can be prepared to form α-glycosidic bonds, and the terminology herein '4-alpha-D-glucopyranosiloxy benzyl alcohol' and a-gastrodine are used interchangeably. The conversion of gastrodigenin to 4-alpha-D-glucopyranosiloxy benzyl alcohol is disclosed in detail in patent application No. 10-2016-0167064 filed by the inventors.

In addition, the ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol provided in this invention are ginsenoside F2 or 4-alpha-D-glucopyranosoxy benzyl alcohol unless there is particular notice. Contains all of the salts, can be used as a wrinkle improvement material. When the ginsenoside F2 or 4-alpha-D-glucopyranosiloxy benzyl alcohol is used in the form of a salt, the ginsenoside F2 or 4-alpha-D-glucopyranosiloxy benzyl alcohol as an active ingredient Among the salts present, it is preferable to select an acceptable salt as an antibacterial agent, an antifungal agent, a food preservative additive, a cosmetic additive or an antifungal pesticide. Typically, the salts include acid addition salts of inorganic acids such as hydrochloride, sulfate, nitrate, phosphate, hydrobromide, hydrochloride, or acetate, oxalate, maronate, sulphate, marinate, fumarate, lactate, And addition salts of organic acids such as malate, citrate, tartarate, methanesulfonate and ethanesulfonate.

As used herein, the term "skin wrinkle" refers to a streak caused by skin attenuation, which may be caused by a gene, a decrease in collagen present in the dermis of the skin, or an external environment.

In the present invention, "prevention or improvement of skin wrinkles" refers to inhibiting or inhibiting generation of wrinkles on the skin or alleviating wrinkles already produced.

The main functions of skin fibroblasts include the regeneration of damaged skin tissue through extracellular matrix synthesis and proliferation.Exogenous aging factors such as photoaging or accumulation of damage caused by free oxygen and cellular aging due to telomeres breakdown They lower the physiological activity of dermal fibroblasts in the dermis. Type I collagen, which accounts for more than 95% of the extracellular matrix of the skin, plays a very important part in the physiological activity of fibroblasts through interactions and signal exchanges with cell adhesion molecules and cytoskeleton. When the synthesis of is decreased, the amount of collagen in the skin tissue is reduced, thereby reducing the surface tension to reduce skin elasticity and the formation of skin wrinkles, as well as reducing the bioactive function, including the proliferation and regeneration of the cells Cause a vicious cycle.

Therefore, collagen of dermal fibroblasts can be seen to be directly related to the repair or regeneration of tissue during skin regeneration, skin elasticity, skin wrinkle formation and skin damage.

That is, when the synthesis of collagen or procollagen of skin fibroblasts or the synthesis of matrix metallo-proteinase (hereinafter referred to as 'MMP') that breaks down collagen is inhibited, skin elasticity improvement, skin regeneration, Effects such as skin wrinkle improvement, wound healing, repair and regeneration of damaged skin tissue, and anti-aging of the skin can be obtained.

The composition comprising ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol of the present invention as an active ingredient has a synergistic effect on the increased expression of type I procollagen gene, and MMP-1 ((matrix metallo) -Protease 1) It is characterized by synergistic effects on the inhibition of gene expression.

Specifically, the composition comprising the ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol of the present invention reduces cytotoxicity in UV-irradiated normal human dermal fibroblasts (NHDF) and degrades collagen degradation. Inhibition of the expression of matrix metallo-proteinase genes that promotes the synergistic effect of increasing the expression of type I procollagen genes, such as increased skin elasticity, skin regeneration, improved skin wrinkles, Wound healing, repair and regeneration of damaged skin tissue; And it can have effects, such as anti-aging of skin. Specifically, it may have an effect of preventing or improving skin wrinkles (see FIGS. 2 to 7).

In the cosmetic composition comprising ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol of the present invention as an active ingredient, the ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol Silver is preferably mixed at a weight ratio of 1: 0.5 to 1.5, and most preferably at a ratio of 1: 1. The ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol are mixed at a weight ratio of 4-alpha-D-glucopyranosiloxy benzyl alcohol 0.5 to 1.5 with respect to 1 weight ratio of ginsenoside F2. It has been shown to have an excellent effect on the suppression of the expression of matrix metallo-proteinase 1 (MMP-1) gene, and may be mixed in a weight ratio of 4-alpha-D-glucopyranosiloxy benzyl alcohol 1 to 1 weight ratio of ginsenoside F2. Was determined to have the highest MMP-1 gene expression inhibitory activity. In particular, the skin wrinkle improvement effect in the experimental group treated with ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol in a weight ratio of 1: 1 and treated at a dose of 10 ug / mL was not irradiated with UVB. The MMP-1 protein production level measured in the negative control was slightly above the level, which is mixed in a weight ratio of 4-alpha-D-glucopyranosiloxy benzyl alcohol 0.5 to 1.5 to 1 weight ratio of ginsenoside F2. The synergistic effect of the combination was confirmed to be very good (see Fig. 6).

In addition, ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol may be mixed in a weight ratio of 0.5 to 1.5 of 4-alpha-D-glucopyranosiloxy benzyl alcohol to 1 weight ratio of ginsenoside F2. It has been shown to be effective in increasing the expression of the excellent type I procollagen gene and is the highest type I pro when mixed in the weight ratio of 4-alpha-D-glucopyranosiloxy benzyl alcohol 1 to the weight ratio of ginsenoside F2. It was determined to have an expression activity of the collagen gene. In particular, the skin wrinkle improvement effect in the experimental group treated with ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol in a weight ratio of 1: 1 and treated at a dose of 10 ug / mL was not irradiated with UVB. Type I procollagen protein production levels measured in the negative control were observed to be above the level, which was mixed in a weight ratio of 4-alpha-D-glucopyranosiloxy benzyl alcohol 0.5 to 1.5 to 1 weight ratio of ginsenoside F2. The synergistic effect of the combination was found to be very good (see FIG. 7).

In addition, ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol contained in the cosmetic composition for preventing or improving skin wrinkles of the present invention has the effect of removing skin wrinkles by itself, and is known in the art. When used in combination with substances known to be effective in preventing and improving skin wrinkles, the effect of preventing and improving skin wrinkles can be maintained.

In addition, the cosmetic composition of the present invention may further include water-soluble vitamins, fat-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.

The water-soluble vitamins may be any compound that can be formulated in cosmetics, but preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H And salts thereof (thiamine hydrochloride, sodium ascorbate salt, etc.) and derivatives (ascorbic acid-2-sodium phosphate salt, ascorbic acid-2-magnesium phosphate salt, etc.) can also be used in the present invention. Included in The water-soluble vitamin can be obtained according to conventional methods such as microbial transformation method, microbial culture purification method, enzyme method or chemical synthesis method.

The fat-soluble vitamins may be any one that can be formulated in cosmetics, but preferably vitamin A, carotene, vitamin D2, vitamin D3, vitamin E, and the like, and derivatives thereof (ascorbic palmitate, ascorbic acid stearate). Bin, dipalmitinate, ascorbate, dl-alpha tocopherol acetate, dl-alpha tocopherol vitamin E, DL-pantothenyl alcohol, D-pantotenyl alcohol, pantothenyl ether, etc.) do.

The polymer peptide may be any compound as long as it can be incorporated into cosmetics, preferably, collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, and the like. The polymer peptide can be purified and obtained according to a conventional method such as a method for purifying a microbial culture, an enzyme method, or a chemical synthesis method, or can be used after being purified from natural products such as dermis such as pigs and cows and silk fibers of silkworms.

The polymer polysaccharide may be any compound as long as it can be blended into cosmetics. Preferably, hydroxyethyl cellulose, xanthan gum, chondroitin sulfate or a salt thereof (sodium salt, etc.) may be mentioned. For example, chondroitin sulfate or its salt, etc. can be normally purified from a mammal or fish.

The sphingolipide may be any compound as long as it can be blended into cosmetics, and preferably, ceramide, phytosphingosine, sphingose sugar lipid, and the like. The sphingolipids can usually be purified from mammals, fish, shellfish, yeasts or plants according to a conventional method or obtained by chemical synthesis.

The seaweed extract may be any one that can be formulated in cosmetics, but may preferably include brown algae extract, red algae extract, green algae extract, and the like, and calginane, arginic acid, and arginic acid purified from these seaweed extracts. Sodium, potassium arginate and the like are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained by purification from seaweed according to a conventional method.

The cosmetic of the present invention may be blended with the above essential components, if necessary, with other ingredients normally blended into the cosmetic.

Examples of the blending component that may be added include oil or fat components, humectants, emollients, ultraviolet absorbers, pH adjusters, flavoring agents, blood circulation accelerators, cooling agents, limiting agents, purified water and the like.

Examples of the fat or oil components include ester fats, hydrocarbon fats, silicone fats, fluorine fats, animal fats, and vegetable fats and oils.

Examples of the ester fats and oils include glyceryl tri2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl mystinate, isopropyl palmitate, ethyl stearate, octyl palmitate, and isocetyl isostearate, Butyl stearate, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocyanate isocetyl, isostearyl mysterylate, isostearyl palmitate, octylate acid octyldodecyl, isocetyl isostearate, diethyl sebacate, Diisopropyl adipropyl, isoalkyl neopentane, tri (capryl, capric acid) glyceryl, trimethyl ethyl trimethylolpropane, trimethyl sterol trimethylolpropane, tetra 2-ethylhexanopentane Slitol, Cetyl Caprylic Acid, Decyl Laurin, Hexyl Lauric Acid, Mycetic Decyl, Myristin Mitrisyl, Myristin Cetyl, Stearyl Stearate, Decyl Oleate, Ricinooleic Acid Cetyl, isostearyl laurate, isotridecyl myristin, isocetyl palmitate, octyl stearate, isocetyl stearate, isodecyl oleate, octyl dodecyl oleate, octyl dodecyl linoleate, isopropyl isopropyl acid, 2-ethylhexanoic acid cetostearyl, 2-ethylhexanoic acid stearyl, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicapric acid, propylene glycol dicaprylic acid, neopentyl glycol dicapric acid Neopentyl glycol dioctanoate, glyceryl tricaprylate, glyceryl triundecylate, glyceryl triisopalmitate, glyceryl triisostearate, octyldodecyl neopentane, isostearyl octanoate, octyl isonanoate , Hexyldecyl neodecanoate, octyldodecyl neodecanoate, isetyl isostearate, isstearyl isostearate, octyldecyl isostearate, polygly Linoleic acid ester, polyglycerin isostearic acid ester, triisoceyl citrate, triisoalkyl citrate, triisooctyl citrate, lauryl lactate, myristyl lactic acid, cetyl lactate, octyl lactate, triethyl citrate, acetyl triethyl citrate, Acetyl tributyl citrate, trioctyl citrate, diisostearyl malic acid, 2-ethylhexyl hydroxystearate, diethyl 2-ethylhexyl, diisobutyl adipicate, diisopropyl sebacinate, dioctyl sebacate, stearic acid Cholesteryl, isostearic acid cholesteryl, hydroxystearic acid cholesterol, oleic acid cholesteryl, oleic acid dihydrocholesteryl, isostearic acid pitsteryl, oleic acid pitsteryl, 12-steloylhydroxy Isocetyl Stearate, 12-Steloylhydroxystearate Stearyl, 12-Steloylhydroxystearate Isostea And the like ester, such as.

Examples of the hydrocarbon-based oils and fats include hydrocarbon-based oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybutene, microcrystalline wax, and vaseline.

The silicone-based fats and oils include polymethylsilicone, methylphenylsilicone, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane methylcetyloxysiloxane copolymer, dimethylsiloxane methylsteoxysiloxane copolymer, and alkyl. Modified silicone oil, amino modified silicone oil and the like.

Perfluoro polyether etc. are mentioned as said fluorine-based fats and oils.

The animal or plant oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, soybean oil, corn oil, rapeseed oil, almond oil, palm kernel oil, palm oil, castor oil, sunflower oil, grape seed oil, cottonseed oil, palm oil, Cucumber nut oil, wheat germ oil, rice germ oil, shea butter, moon sour colostrum, marker demia nut oil, egg yolk oil, tallow, horse oil, mink oil, orange rape oil, jojoba oil, canderry wax, carnauba wax, liquid ranol And animal or plant fats and oils such as hardened castor oil.

Examples of the moisturizing agent include a water-soluble low molecular moisturizer, a fat-soluble molecular moisturizer, a water-soluble polymer, and a fat-soluble polymer.

As the water-soluble low molecular moisturizer, serine, glutamine, sorbitol, mannitol, pyrrolidone-sodium carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B (polymerization degree n = 2 or more), Polypropylene glycol (polymerization degree n = 2 or more), polyglycerol B (polymerization degree n = 2 or more), lactic acid, lactic acid salt, etc. are mentioned.

Examples of the fat-soluble low molecular humectants include cholesterol and cholesterol esters.

Examples of the water-soluble polymer include carboxyvinyl polymer, polyasparaginate, tragacanth, xanthan gum, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, water soluble chitin, chitosan, and dextrin. Can be mentioned.

Examples of the fat-soluble polymer include polyvinylpyrrolidone eicosene copolymer, polyvinylpyrrolidone hexadecene copolymer, nitrocellulose, dextrin fatty acid ester, polymer silicone, and the like.

Examples of the emollient include long-chain acyl glutamic acid cholesteryl ester, hydroxy stearic acid cholesterol, 12-hydroxystearic acid, stearic acid, rosin acid, lanolin fatty acid cholesteryl ester, and the like.

Examples of the ultraviolet absorber include paraaminobenzoic acid, ethyl paraaminobenzoate, amyl paraaminobenzoic acid, octyl paraaminobenzoate, ethylene glycol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomentyl salicylate, Cinnamic acid benzyl, paramethoxy cinnamic acid-2-ethoxyethyl, paramethoxy cinnamic acid octyl, diparamethoxy cinnamic acid mono-2-ethylhexane glyceryl, paramethoxy cinnamic acid isopropyl, diisopropyl diisopropyl cinnamic acid ester mixture , Urocanoic acid, ethyl urocanate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenonesulfonic acid and salts thereof, dihydroxymethoxybenzophenone, dihydroxymethoxybenzophenone disulfonate, dihydroxy Benzophenone, tetrahydroxybenzophenone, 4-tert-butyl-4'-methoxydibenzoylmethane, 2,4,6-trianilino-p- (carbo-2'-ethylhexyl-1'-oxy) -1,3,5-triazine, 2- (2-hi And the like can be mentioned hydroxy-5-methylphenyl) benzotriazole.

Examples of the pH adjuster include citric acid, sodium citrate, malic acid, sodium malate, fmaric acid, sodium fmarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate, and the like.

Moreover, the compounding component which may be added other than this is not limited to this, Moreover, Although all said components can be mix | blended within the range which does not impair the objective and effect of this invention, Preferably it is 0.01-5 weight part with respect to a total weight, More preferably, it may be blended in 0.01 to 3 parts by weight.

Cosmetics prepared by containing the composition of the present invention may take the form of solutions, emulsions, viscous mixtures and the like.

In addition, the components included in the cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the components as an active ingredient, for example, conventional auxiliaries such as stabilizers, pigments and natural flavors and It may further include a carrier.

The composition of the present invention can be used in various ways, such as cosmetics or facial cleansers having an effect of preventing and improving skin wrinkles.

As a product to which the composition of the present invention can be added, for example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nourishing lotion, massage cream, nourishing cream, moisturizing cream, hand cream Cosmetics such as foundation, essence, nutrition essence, mask pack and the like, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser.

When the formulation of the present invention is a paste, cream or gel, animal carriers, vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc. may be used as carrier components. Can be.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellants such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the dosage form of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

According to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or improving skin wrinkles comprising ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol as an active ingredient.

In addition, in the pharmaceutical composition for preventing or improving skin wrinkles of the present invention, the ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol increase the expression of the type I procollagen gene, and MMP-1. It is characterized in that there is a synergistic effect in suppressing the expression of the gene.

In the pharmaceutical composition comprising ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol of the present invention as an active ingredient, the ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl The alcohol is characterized in that mixed in a weight ratio of 1: 0.5 to 1.5.

The composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

Pharmaceutical dosage forms of the compositions of the invention may also be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination with other pharmaceutically active compounds.

Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

When formulating the composition of the present invention, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.

The composition of the present invention is administered directly to the skin in the form of an external preparation for application to the skin in the form of an external preparation for creams, gels, patches, sprays, ointments, warnings, lotions, linens, pastas or cataplasmas. It may be, but is not limited thereto.

Preferred dosages of the mixed compositions of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration of administration, and may be appropriately selected by those skilled in the art, preferably 0.01 μg / ml to 25 It may be administered at a dose of μg / ml. Topical administration may be administered once a day or may be divided several times.

As another aspect, the present invention provides a food composition for preventing or improving skin wrinkles comprising ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol as an active ingredient.

In a food composition for preventing or improving skin wrinkles comprising ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol of the present invention, the ginsenoside F2 and 4-alpha-D-glu Copyranosiloxy benzyl alcohol is characterized in that it is mixed in a weight ratio of 1: 0.5 to 1.5.

When the composition of the present invention is used as a nutraceutical additive, the composition may be added as it is or used with other nutraceutical or nutraceutical ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the intended use. In general, the composition of the present invention may be added in the amount of preferably 15 parts by weight or less, more preferably 10 parts by weight or less based on the raw material in the manufacture of food or beverage. However, in the case of long-term intake for the purpose of health control and hygiene, the amount may be below the above range, and there is no problem in terms of stability, so the active ingredient may be used in an amount above the above range.

There is no particular limitation on the type of dietary supplement of the present invention. Examples of health functional foods to which the composition may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, beverages, teas, Drinks, alcoholic beverages and vitamin complexes, and the like, may include all of the health functional foods in a conventional sense, and may include foods used as feed for animals.

In addition, when the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweeteners, flavors or natural carbohydrates and the like as an additional ingredient, as in a conventional beverage. The natural carbohydrate can be glucose, monosaccharides such as fructose, malsaccharides, disaccharides such as sucrose, polysaccharides such as dextrins, cyclodextrins, and sugar alcohols such as xylitol, sorbitol, erythritol. The ratio of the natural carbohydrate is not limited thereto, but may be preferably about 0.01 to 0.04 g, more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention. The sweetener may be a natural sweetener such as taumartin, stevia extract and a synthetic sweetener such as saccharin, aspartame.

In addition to the above, the nutraceutical composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents used in carbonated drinks, and the like. Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks.

Since the cosmetic, pharmaceutical, and food compositions of the present invention have the effect of preventing or improving skin wrinkles per se, they can be directly used as a composition for preventing or improving skin wrinkles, and contain natural extracts effective for preventing and improving skin wrinkles. It can also be used in the form of mixing with other ingredients that are expected to be able to enhance the existing skin wrinkle prevention or improvement more.

As described above, the composition comprising ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol of the present invention as an active ingredient inhibits the expression of MMP-1 in human dermal fibroblasts, and Type I By increasing the production of procollagen and inhibiting the expression of IL-6 protein, it has a synergistic effect in preventing the occurrence of skin wrinkles and improving the wrinkles of damaged skin. Overall, the compositions of the present invention can prevent and greatly improve skin wrinkles.

In addition, the composition of the present invention is not only very safe for human body, but also excellent in stability.

1 is a graph showing the effect of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol on cell survival.
2 is a graph showing the antioxidant activity of the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol.
3 is a graph showing the expression inhibitory effect of the MMP-1 protein of the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol in human fibroblasts.
4 is a graph showing the expression promoting effect of the type I procollagen protein of the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol in human fibroblasts.
5 is a graph showing the expression inhibitory effect of the IL-6 protein of the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol in human fibroblasts.
Figure 6 is a graph showing the effect of inhibiting the expression of MMP-1 protein according to the compounding ratio of the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol with different mixing ratios.
Figure 7 is a graph showing the effect of increasing the expression of type I procollagen protein according to the compounding ratio of the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol with different mixing ratios.

Hereinafter, the present invention will be described in more detail with reference to Examples. Since these examples are only for illustrating the present invention, the scope of the present invention is not to be construed as being limited by these examples.

Example  Ginsenoside F2 and 4-alpha-D- Glucopyranosiloxy benzyl  Preparation of alcohol

Ginseng was washed with purified water and then crushed into small pieces, and ethanol 7 to 8 times the dry weight was added. The mixture was boiled and refluxed at 100 ° C. for 2 hours, filtered to obtain an extract, followed by evaporation of ethanol to obtain a ginseng extract. Ginseng extract extract was dissolved in a water-soluble solvent, and the microorganism-derived pectinase was added and reacted at 20-60 ° C. for 24 to 72 hours to obtain aglycon (glycon) containing ginsenoside F2. Thus obtained aglycon (aglycon) using a mixed solvent of purified water and ethanol as the developing solvent was fractionated only the fraction containing ginsenoside F2 by column chromatography to prepare a ginsenoside F2.

50 g of starch (sugar starch) and 4.0 g of 4-hydroxy benzyl alcohol (4HBA) as sugar acceptor were prepared, and 2,250 U of CGTase stored in 1 ml of 0.1 M CaCl ₂ solution and the prepared sugar donor and sugar acceptor were prepared. 0.1 M phosphate acetate buffer (pH 6.0) was added, and the volume was adjusted to 100 mL. The reaction solution was reacted for 48 hours with stirring in the dark at 50 ° C., and then heated in a boiling water bath for 10 minutes to inactivate the enzyme. Subsequently, in order to hydrolyze malto-oligosylglucosides produced by the reaction with CGTase to monoglucoside, the pH of the reaction solution was adjusted to 5.0 using 1.0 M acetic acid solution, followed by glucoamylase. 80 units (U) were added and hydrolyzed for 8 hours with stirring at 50 ° C. The reaction solution was heated in a boiling water bath for 10 minutes to inactivate glucoamylase and used as a sample for reaction product separation by column chromatography.

As one of the processes for the glycoside separation produced by the sugar transfer reaction, the free form of aromatic alcohols remaining in each reaction solution was first extracted and removed with chloroform. Subsequently, the reaction solution was adsorbed onto a Diaion HP-20 packed column (3 cm × 30 cm), washed with 200 mL of distilled water to remove saccharides, and the resulting glycoside was eluted using 200 mL of methanol. The methanol eluate was concentrated under reduced pressure, and then further separated by silica gel column chromatography. Chromatography fills approximately 50 times the amount of silica gel (70-230 mesh) in a glass column (3cm × 25cm) and then mixes chloroform-methanol-water as a solvent (80: 20: 2, 70: 30: 3). , 65:35; 10, v / v) to sequentially dissociate 4-alpha-D-glucopyranosoxyoxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol).

Example  2. Check for cytotoxicity

Cytotoxicity was measured using MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) colorimetric assay. Methyl thiazol tetrazolium (MTT) assays are used to measure cell viability, turning MTT into a formazan stain that produces purple. After 72 hours of incubation, the volume of medium was reduced to 1 ml and 100 μl of 1 mg / ml MTT was added to each wall. The cells were then incubated at 37 ° C. for 2 hours in the presence of 5% CO ₂ and 95% O ₂ . Substrate-containing medium was removed and 1 ml of DMSO was added to each wall to dissolve the formarzan crystals. In addition, the plate was shaken with an orbital shaker for 30 minutes at room temperature. The absorption of 100 μl aliquots was quantified by measuring the absorption at 570 nm using a microplate reader (Molecular Devices E09090; San Francisco, CA, USA).

To determine the cytotoxicity of cells treated with ginsenoside F2, 4-alpha-D-glucopyranosiloxy benzyl alcohol, and combinations thereof (72 hours after treatment), in UVB-irradiated normal human dermal fibroblasts MTT analysis was performed.

As a result, as shown in FIG. 1, after UVB irradiation, treatment with ginsenoside F2, 4-alpha-D-glucopyranosiloxy benzyl alcohol, and complex compounds thereof inhibited cell survival of human dermal fibroblasts. Rather, it could be confirmed that it promotes growth (FIG. 1).

Example  3. Antioxidant Effect Verification

Experiments were performed to determine the inhibitory effect of the formation of reactive oxygen species (ROS) on the combination of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol in human skin fibroblasts.

The experiment was performed by irradiating human skin fibroblasts with UVB (UVB Peak range: 312 nm, UV dose: 144 mJ / cm ² ), and then ginsenoside F2 and 4-alpha-D-glucopyrano diluted with serum-free DMEM medium. The siloxy benzyl alcohol, and combinations thereof were treated by concentration (0.1, 1, 10 μg / μl) and incubated for 30 minutes, and the fluorescence was measured under excitation at 480 nm and emission at 530 nm. It was performed by comparing the fluorescence intensity (DCF fluorescence intensity). Statistical processing was performed using the GraphPad Prism program, and the significance of the mean value was examined with a limit of less than 5% using ANOVA (one-way analysis of variance).

As a result, a complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol (1: 1 than the ginsenoside F2 or 4-alpha-D-glucopyranosiloxy benzyl alcohol alone treatment) Weight ratio), the antioxidant effect was shown to be more excellent, this phenomenon was observed more clearly in the UV-treated human skin fibroblast experiment. Therefore, it was confirmed that the combination of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol significantly inhibited ROS production and had a synergistic effect on antioxidant (see FIG. 2).

Example  4. MMP -1 protein synthesis inhibition

2 ml of DMEM was added to a 40 mm cell culture dish, and human skin fibroblasts were inoculated at a concentration of about 1.2 × 10 ⁵ , followed by incubation for 24 hours at 37 ° C. and 5% CO ₂ . Thereafter, UVB was irradiated at 144mJ / cm ² condition, and ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol obtained in Example 1 and their complex compounds (1: 1 weight ratio, respectively) 0.1, 1, and 10 μg / ml) and cultured for 3 days. Afterwards, the culture was harvested and centrifuged at 4 ° C. and 7500 rpm for 5 minutes using an ELISA method, MMP-1 (Human Total MMP-1 kit, R & D Systems, Inc., Minneapolis, MN, USA). The amount of protein expression change was confirmed.

First, in human skin fibroblast experiments without UV irradiation, it was found that the combination of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol inhibits the production of MMP-1 protein in a concentration dependent manner. . Experimental groups treated with ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol simultaneously in all 0.1, 1, and 10 μg / ml treatment groups had significantly improved MMP compared to their treatment alone. It was observed to show the inhibitory effect of the production of -1 protein, it was confirmed that there is a synergistic effect on the combination of ginsenoside F2 and 4-alpha-D- glucopyranosiloxy (FIG. 3).

In addition, human dermal fibroblasts treated with UV radiation at a dose of 144 mJ / cm ² increased the production of MMP-1 protein by more than four times compared to the UV-treated group. This increase in production of MMP-1 protein due to UV irradiation treatment was significantly reduced by the treatment of the complex compound of ginsenoside F2 and 4-alpha-D- glucopyranosiloxy benzyl alcohol. It was observed that treatment of the complex compound in all of the 1, 10, and 100 μg / ml treatment groups showed a significantly improved inhibitory effect on the production of MMP-1 protein compared to the single treatment group (FIG. 3).

Through the above results, the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol of the present invention effectively inhibits the production of MMP-1 protein, which causes wrinkles, to wrinkle the skin. It could be effectively used for the prevention and improvement of, ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol was found to have a synergistic effect.

Example  5. Type 1 Procollagen  Promote the synthesis of protein

2 ml of DMEM was added to a 40 mm cell culture dish, and human skin fibroblasts were inoculated at a concentration of about 1.2 × 10 ⁵ , followed by incubation for 24 hours at 37 ° C. and 5% CO ₂ . Thereafter, UVB was irradiated at 144mJ / cm ² condition, and then ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol prepared in Example 1 and combinations thereof (0.1, 1, and 10, respectively) Cultured for 3 days by replacing with a medium containing μg / ml). Afterwards, the culture was harvested and centrifuged at 4 ° C. and 7500 rpm for 5 minutes to change protein expression levels of type 1 procollagen (Procollagen Type IC Peptide EIA Kit, Takara, Shiga, Japan) using the ELISA method. It was confirmed.

First, in human dermal fibroblast experiments without UV irradiation, the complex compound treatment group of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol increases the production of type 1 procollagen protein in a concentration dependent manner. And it was found.

In addition, human skin fibroblasts treated with UV radiation at a dose of 144 mJ / cm ² reduced the production of type 1 procollagen protein by about three times as compared to the UV-treated group. This reduction in production of type 1 procollagen protein due to UV irradiation showed a phenomenon of increasing again with the treatment of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol complex compound. In addition, the composite compound treated group of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol showed a significantly improved effect of increasing the production of type 1 procollagen protein compared to their monotreated group. Was observed (FIG. 4). Through the above results, the composition comprising ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol of the present invention acts on the TGF-β / Smad signaling system to produce type 1 procollagen. , And by inhibiting the expression of the collagen degrading enzyme MMP-1, it was confirmed that the effect can effectively prevent wrinkles, improve the generated wrinkles, ginsenoside F2 and 4-alpha- Synergistic effect was confirmed due to the combination of D- glucopyranosiloxy benzyl alcohol.

Example  6. Verification of IL-6 protein expression inhibitory effect

Inflammatory mediators such as IL-6 are involved in the inflammatory response mechanisms caused by skin cell damage, and the inflammatory response is amplified due to the action of the inflammatory mediators. It becomes possible.

To test the effect of the combination of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol on the expression of IL-6 protein, we tested the mouse macrophage RAW 264.7 cells. Was performed. RAW 264.7 cells were seeded in a 96 well plate at a concentration of 1.0 × 10 ⁵ and then incubated for 24 hours under 37 ° C., 5% CO ₂ wet conditions. Then, after washing with PBS solution, each well treated with LPS 1 ㎍ / ㎖ alone or with various concentrations of samples and incubated for 24 hours. Normal control was treated only with medium.

After the incubation, the supernatant was collected and analyzed for IL-6 protein production using an enzyme-linked immunosorbent assay (ELISA) kit.

As a result, it was shown that the production of LPS-induced IL-6 protein was inhibited when the complex extract of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol was treated. Inhibitory activity was found to be concentration dependent (see FIG. 5). In addition, it was observed that the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol showed a significantly improved inhibitory effect on IL-6 protein production compared to their monotherapy group. It was confirmed that there is a synergistic effect due to the combination of senoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol.

Example  7. Ginsenoside F2 and 4-alpha-D- Glucopyranosiloxy benzyl  Derivation of the optimal combination ratio of alcohol

The experiments of Examples 3 to 6 confirmed synergistic effects on skin wrinkle improvement and antioxidant activity of the combination of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol. The experiment was performed by varying their mixing ratio for derivation.

7-1. MMP -1 Optimal Rate of Protein Synthesis Inhibition

Experiment by the same method as in Example 4, except that the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol in a weight ratio of 10: 1 to 1:10 The experiment was repeated three times.

As a result, the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol has a ratio of 0.5 to 1.5 of 4-alpha-D-glucopyranosiloxy benzyl alcohol to 1 weight ratio of ginsenoside F2. It has been shown to have an excellent inhibitory effect on the production of MMP-1 protein when mixed in weight ratio and the highest MMP when ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol are mixed in a weight ratio of 1: 1. -1 protein production inhibitory activity was measured.

In particular, the skin wrinkle improvement effect of the ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol in a dose ratio of 10 µg / ml mixed at a weight ratio of 1: 1 was not investigated by UVB. MMP-1 protein production levels measured in the non-negative control group was found to be similar to, and mixed with a weight ratio of 4-alpha-D-glucopyranosiloxy benzyl alcohol 0.5 to 1.5 compared to 1 weight ratio of ginsenoside F2. It was confirmed that the synergistic effect of the combination is very excellent (see Fig. 6).

7-2. Type 1 Procollagen  Optimal rate of protein synthesis promotion

In the same manner as in Example 5, except that the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol was mixed in a weight ratio of 10: 1 to 1:10. The experiment was repeated three times.

As a result, the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol has a ratio of 0.5 to 1.5 of 4-alpha-D-glucopyranosiloxy benzyl alcohol to 1 weight ratio of ginsenoside F2. It has been shown to have an excellent type 1 procollagen protein production promoting effect when mixed at a weight ratio, the highest when ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol are mixed at a weight ratio of 1: 1. It was determined to have type 1 procollagen protein production promoting activity.

In particular, the skin wrinkle improvement effect of ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol at a dose ratio of 10 µg / ml in a weight ratio of 1: 1 was not investigated by UVB irradiation. It was found to be similar to the type 1 procollagen protein synthesis level measured in the control group, which is mixed with a weight ratio of 4-alpha-D-glucopyranosiloxy benzyl alcohol 0.5 to 1.5 to 1 weight ratio of ginsenoside F2. It was confirmed that the synergistic effect of the combination is very excellent (see Fig. 7).

Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that such a specific technology is only a preferred embodiment, and the scope of the present invention is not limited thereto.

Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Claims (9)

Ginsenoside F2 and 4-alpha-D-glucopyranosoxyoxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) comprising a cosmetic composition for preventing or improving skin wrinkles. The method of claim 1,
The ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) increase the expression of the type I procollagen gene, and MMP-1 (matrix metallo-proteinase). 1) Cosmetic composition for preventing or improving skin wrinkles, characterized by inhibiting the expression of the gene. The method of claim 1,
The ginsenoside F2 and 4-alpha-D-glucopyranosoxyoxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) is a skin wrinkle prevention or improvement, characterized in that mixed in a weight ratio of 1: 0.5 to 1.5. Cosmetic composition for. The method of claim 1,
The composition includes skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, mask pack, soap, cleansing Cosmetic composition for preventing or improving skin wrinkles, characterized in that any one selected from foam, cleansing lotion, cleansing cream, body lotion and body cleanser. Pharmaceutical composition for preventing or improving skin wrinkles comprising ginsenoside F2 and 4-alpha-D-glucopyranosoxyoxy benzyl alcohol as an active ingredient. The method of claim 5,
The ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) is a skin wrinkle prevention or improvement, characterized in that mixed in a weight ratio of 1: 0.5 to 1.5. Pharmaceutical composition for. The method of claim 5,
The pharmaceutical composition is any one of the formulations selected from creams, gels, patches, sprays, ointments, warnings, lotions, linen, pasta and cataplasma for the prevention or improvement of skin wrinkles Composition. Ginsenoside F2 and 4-alpha-D-glucopyranosiloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) comprising a food composition for preventing or improving skin wrinkles. The method of claim 8,
The ginsenoside F2 and 4-alpha-D-glucopyranosoxyoxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) is a skin wrinkle prevention or improvement, characterized in that mixed in a weight ratio of 1: 0.5 to 1.5. Food composition.

Images